CTD stands for Common Technical Document, which is a standardized format for organizing and presenting data for regulatory submissions in the pharmaceutical industry. It was developed by the International Conference on Harmonisation (ICH) to streamline the drug approval process across different regulatory agencies worldwide.
The CTD structure consists of five modules that cover quality, safety, and efficacy information for drug products. This harmonized format facilitates efficient review by regulatory authorities and promotes consistency in drug applications across different countries and regions.
The CTD is crucial in clinical research as it provides a standardized framework for organizing and presenting data from drug development programs. This standardization enhances the efficiency of regulatory reviews, facilitating faster and more consistent drug approval processes across different regulatory agencies worldwide.
Furthermore, the CTD format ensures that all necessary information is included in regulatory submissions, reducing the likelihood of delays due to incomplete or poorly organized data. By adopting this globally recognized structure, pharmaceutical companies can streamline their development and submission processes, potentially accelerating the time-to-market for new therapies.
Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…
The Axcellant team recently attended the International Conference on Nuclear Cardiology (ICNC) in Berlin – one of the most important…
Axcellant is pleased to announce the formation of its Advisory Board - a group of distinguished experts in clinical science,…
Copyright @ 2026 Axcellant